{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:59:41Z","timestamp":1788303581321,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Investigator Studies Progam"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ceftolozane\/tazobactam (C\/T) is indicated for the treatment of complicated intra-abdominal infection (IAI), complicated urinary tract infection (UTI), and hospital-acquired\/ventilator-associated bacterial pneumonia caused by susceptible bacteria. As real-world data are limited, we report utilization and associated outcomes of C\/T use in the outpatient setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a multicenter, retrospective study of patients who received C\/T between May 2015 and December 2020. Demographics, infection types, C\/T utilization characteristics, microbiology, and health care resource utilization were collected. Clinical success was defined as complete or partial symptom resolution at completion of C\/T. Persistent infection and discontinuation of C\/T were deemed nonsuccess. Logistic regression analysis was used to identify predictors associated with clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 126 patients (median age, 59 years; 59% male; median Charlson index, 5) from 33 office infusion centers were identified. Infection types included 27% bone and joint infection (BJI), 23% UTI, 18% respiratory tract infection (RTI), 16% IAI, 13% complicated skin and soft tissue infection (cSSTI), and 3% bacteremia. The median daily dose of C\/T was 4.5\u2005g, primarily administered via elastomeric pumps as intermittent infusion. The most common gram-negative pathogen was P. aeruginosa (63%), 66% of which was multidrug-resistant and 45% carbapenem-resistant. Enterobacterales was identified in 26% of isolates, of which 44% were extended-spectrum beta-lactamase producers. The overall clinical success rate of C\/T was 84.7%. Nonsuccessful outcomes were due to persistent infections (9.7%) and drug discontinuations (5.6%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>C\/T was successfully used in the outpatient setting to treat a variety of serious infections with a high prevalence of resistant pathogens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad173","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T01:14:02Z","timestamp":1680052442000},"source":"Crossref","is-referenced-by-count":14,"title":["A Real-world Multicenter Outpatient Experience of Ceftolozane\/Tazobactam"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-096X","authenticated-orcid":false,"given":"Lucinda J","family":"Van Anglen","sequence":"first","affiliation":[{"name":"Healix Infusion Therapy, LLC , Sugar Land, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5161-4836","authenticated-orcid":false,"given":"Claudia P","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Healix Infusion Therapy, LLC , Sugar Land, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-9222","authenticated-orcid":false,"given":"Kimberly A","family":"Couch","sequence":"additional","affiliation":[{"name":"Healix Infusion Therapy, LLC , Sugar Land, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"2023050914210778900_ofad173-B1","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050914210778900_ofad173-B2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2023050914210778900_ofad173-B3","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023050914210778900_ofad173-B4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023050914210778900_ofad173-B5","author":"US Food and Drug Administration"},{"key":"2023050914210778900_ofad173-B6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/1060028017701938","article-title":"Use of continuous-infusion ceftolozane\/tazobactam in a multidrug-resistant Pseudomonas aeruginosa urinary tract infection in the outpatient setting","volume":"51","author":"Jones","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2023050914210778900_ofad173-B7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023050914210778900_ofad173-B8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escola-Verge","year":"2018","journal-title":"Infection"},{"key":"2023050914210778900_ofad173-B9","doi-asserted-by":"publisher","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023050914210778900_ofad173-B10","doi-asserted-by":"publisher","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023050914210778900_ofad173-B11","doi-asserted-by":"publisher","first-page":"ofaa014","DOI":"10.1093\/ofid\/ofaa014","article-title":"Clinical and safety evaluation of continuously infused ceftolozane\/tazobactam in the outpatient setting","volume":"7","author":"Jones","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023050914210778900_ofad173-B12","doi-asserted-by":"crossref","first-page":"e02291","DOI":"10.1128\/AAC.02291-19","article-title":"Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections","volume":"64","author":"Jorgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050914210778900_ofad173-B13","doi-asserted-by":"publisher","first-page":"ofab089","DOI":"10.1093\/ofid\/ofab089","article-title":"A multicenter evaluation of ceftolozane\/tazobactam treatment outcomes in immunocompromised patients with multidrug-resistant Pseudomonas aeruginosa infections","volume":"8","author":"Hart","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023050914210778900_ofad173-B14","doi-asserted-by":"crossref","first-page":"106158","DOI":"10.1016\/j.ijantimicag.2020.106158","article-title":"Use of continuous-infusion ceftolozane\/tazobactam for resistant gram-negative bacterial infections: a retrospective analysis and brief review of the literature","volume":"56","author":"Sheffield","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023050914210778900_ofad173-B15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2017.11.003","article-title":"Ceftolozane\/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes","volume":"51","author":"Dietl","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023050914210778900_ofad173-B16","article-title":"Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa","volume":"2018","author":"Hassan","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2023050914210778900_ofad173-B17","article-title":"Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series","volume":"11","author":"Tan","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"2023050914210778900_ofad173-B18","doi-asserted-by":"publisher","first-page":"ofaa409","DOI":"10.1093\/ofid\/ofaa409","article-title":"Outpatient parenteral antimicrobial therapy with ceftolozane\/tazobactam via continuous infusion for multidrug-resistant Pseudomonas aeruginosa osteomyelitis","volume":"7","author":"\u00c1lvarez Otero","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023050914210778900_ofad173-B19","doi-asserted-by":"crossref","first-page":"115302","DOI":"10.1016\/j.diagmicrobio.2020.115302","article-title":"Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012\u20132018)","volume":"100","author":"Shortridge","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023050914210778900_ofad173-B20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC beta-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023050914210778900_ofad173-B21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1128\/AAC.02253-13","article-title":"Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates","volume":"58","author":"Snydman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050914210778900_ofad173-B22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-009-8342-x","article-title":"Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections","volume":"37","author":"Montero","year":"2009","journal-title":"Infection"},{"key":"2023050914210778900_ofad173-B23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1179\/joc.2006.18.6.648","article-title":"Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis","volume":"18","author":"Tascini","year":"2006","journal-title":"J Chemother"},{"key":"2023050914210778900_ofad173-B24","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jac\/dkm357","article-title":"Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review","volume":"60","author":"Zavascki","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2023050914210778900_ofad173-B25","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijantimicag.2018.02.008","article-title":"Evidence of clinical response and stability of ceftolozane\/tazobactam used to treat a carbapenem-resistant Pseudomonas aeruginosa lung abscess on an outpatient antimicrobial program","volume":"51","author":"Stewart","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023050914210778900_ofad173-B26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14787210.2020.1810566","article-title":"Recent innovations and new applications of outpatient parenteral antimicrobial therapy","volume":"19","author":"Farmer","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023050914210778900_ofad173-B27","doi-asserted-by":"crossref","first-page":"S805","DOI":"10.1093\/ofid\/ofaa439.1805","article-title":"1625. Real-world outpatient utilization of ceftolozane\/tazobactam in physician office infusion centers (OICs)","volume":"7","author":"Van Anglen","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023050914210778900_ofad173-B28","doi-asserted-by":"crossref","first-page":"S704","DOI":"10.1093\/ofid\/ofy210.2020","article-title":"2367. Infection incidence and utilization of antimicrobials in physician office infusion centers (POICs)","volume":"5","author":"Van Anglen","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023050914210778900_ofad173-B29","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/ejhpharm-2019-002093","article-title":"Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study","volume":"27","author":"Raby","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"2023050914210778900_ofad173-B30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.curtheres.2017.03.002","article-title":"Chemical stability of ceftolozane\/yazobactam in polyvinylchloride bags and elastomeric pumps","volume":"84","author":"Terracciano","year":"2017","journal-title":"Curr Ther Res Clin Exp"},{"key":"2023050914210778900_ofad173-B31","doi-asserted-by":"crossref","first-page":"dlab141","DOI":"10.1093\/jacamr\/dlab141","article-title":"Assessment of ceftolozane\/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy","volume":"3","author":"Jamieson","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023050914210778900_ofad173-B32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023050914210778900_ofad173-B33","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"2023050914210778900_ofad173-B34","doi-asserted-by":"crossref","first-page":"e01026","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/tazobactam resistance and mechanisms in carbapenem-nonsusceptible Pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"mSphere"},{"key":"2023050914210778900_ofad173-B35","doi-asserted-by":"publisher","first-page":"ofab320","DOI":"10.1093\/ofid\/ofab320","article-title":"Ceftolozane\/tazobactam and Imipenem\/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards-SMART United States 2017\u20132019","volume":"8","author":"Lob","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad173\/49678656\/ofad173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/5\/ofad173\/50255003\/ofad173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/5\/ofad173\/50255003\/ofad173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T02:33:00Z","timestamp":1683772380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad173\/7091592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad173","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,3,28]]},"article-number":"ofad173"}}